Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | SMPD3 | Q9NY59 | 4/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16283752 | 0.95 | PDE10A (0.48) | PDE10ASMPD3NCF1PIK3R1PIK3CA | |
| SCHEMBL2587774 | 0.85 | PDE10A (0.67) | PDE10ANCF1PIK3R1PIK3CACNR2 | |
| SCHEMBL2586042 | 0.85 | CNR2 (0.44) | PDE10ASMPD3NCF1PIK3R1PIK3CA | |
| SCHEMBL2575429 | 0.84 | SMPD3 (0.52) | PDE10ASMPD3NCF1PIK3R1PIK3CA | |
| SCHEMBL2575482 | 0.77 | PDE10A (0.61) | PDE10APIK3R1PIK3CACNR2MAPT | |
| SCHEMBL25341102 | 0.73 | PIK3R1 (0.49) | PDE10ANCF1PIK3R1PIK3CACNR2 | |
| SCHEMBL16283746 | 0.73 | PDE10A (0.58) | PDE10APIK3R1PIK3CAMAPT | |
| SCHEMBL2584005 | 0.72 | PDE10A (0.53) | PDE10ASMPD3NCF1HPGDTSHR | |
| SCHEMBL11542883 | 0.71 | KDM4E (0.53) | SMPD3NCF1HPGDTSHRNPSR1 | |
| SCHEMBL1826556 | 0.70 | SMPD3 (0.62) | PDE10ASMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493889-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2493889-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-8716282-B2 | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN-CILAG, S.A. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN-CILAG, S.A. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN-CILAG, S.A. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | disclosed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | disclosed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | disclosed |
| WO-2011051342-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | PDE10A 2/4885SMPD3 64/4885NCF1 3969/4885 |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | PDE10A 2/4885SMPD3 64/4885NCF1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.